Thank you for your interest in the dementia research at QBI’s Clem Jones Centre for Ageing Dementia Research.   

The Clem Jones Centre for Ageing Dementia Research (CJCADR) is driven by the insight that fundamental, basic research is required to provide a solution to neurodegenerative diseases, in particular those affecting older people, including Alzheimer's disease. These approaches converge around four priorities: 

  • to understand the pathomechanisms of dementia; 
  • to develop new technologies and tools that help us understand pathological processes;
  • to develop novel diagnostics and biomarkers; and 
  • to design new treatments and preventive approaches. 

Primarily established to support fundamental brain research at a cellular and molecular level, CJCADR discoveries are moving toward clinical studies and trials, including planning for a phase I clinical trial that will involve a small number of patients and will explore whether the ultrasound technique discovered at QBI in 2015 is safe to use in the fight against Alzheimer’s disease.

The technology, which temporarily opens the blood-brain barrier enabling the clearance of toxic protein plaques from the brain, has successfully reversed Alzheimer’s symptoms, and restored memory function in animal models. The phase I clinical safety trial is the one of the steps in the development pathway to bring this exciting technology from initial discovery to application.



What stage is QBI at with dementia research? 

The Clem Jones Centre for Ageing Dementia Research brings researchers with different expertise together within QBI to focus efforts on dementia. Since being established in 2013, our researchers have made a number of scientific discoveries including those related to our promising ultrasound technology. Progress within the ultrasound technology program includes: 

  • The breakthrough discovery, published in 2015, that ultrasound can clear the toxic amyloid-beta plaque build-ups that are the hallmark of Alzheimer’s disease.​
  • That repeated treatments with ultrasound in mice are effective in clearing toxic protein plaques from the brain and restoring memory function, without the need for additional therapeutic drugs.
  • That the non-invasive ultrasound technique can be used safely on older rodents.
  • Progression to a large animal model with more similarities with humans and confirmation that the ultrasound technique is safe in that model.
  • Expansion of the research team to includes specialist medical device engineers who are designing the ultrasound equipment.
  • Developing immunotherapies with potential to enhance the effectiveness of the ultrasound technology. 


When will the treatment be available for those living with dementia? 

It is too early to give a definitive answer. As an indication, the average timeframe from the point of discovery to a treatment being available is 15 years. The initial ultrasound discovery was made in 2015. 

What is a clinical trial? 

Clinical trials are research investigations in which people volunteer to test new medical treatments, devices, interventions or diagnostic tests as part of their development from research discovery into clinical use. Clinical trials are run over three phases. The first stage of a clinical trial is phase I, which determines safety but not whether the treatment is effective. If a safety trial concludes successfully, then later-stage clinical trials investigate whether the treatment works and fine-tunes how much of the treatment is needed for an effective result. 


When will the ultrasound clinical trial commence? 

The Queensland Brain Institute at UQ has partnered with a Clinical Research Organisation to conduct the phase 1 safety trial, which will be run in Brisbane, Australia. Working with a Clinical Research Organisation is in line with best practice for clinical trials to ensure trials are run independently and with the highest level of trial expertise and experience. The exact commencement date for recruitment and the specific location of the trials is yet to be determined. 


What will the trials involve? 

The ultrasound approach has been shown to be effective in mouse models of Alzheimer’s disease. Initial studies in sheep indicate that ultrasound is safe to use in a larger animal model. The next stage of the process is to test that the technology is safe in humans. A phase I clinical trial is designed to establish that scanning ultrasound is safe for human use. Once the technology has been deemed safe, subsequent, later phase clinical trials will determine whether ultrasound is an effective treatment for dementia. 


What is the overarching aim of the trial? 

The initial phase 1 trial aims to confirm that scanning ultrasound is a safe, non-invasive treatment for dementia. Subsequent trials will then aim to establish the use of scanning ultrasound an effective treatment for Alzheimer’s disease. In parallel, QBI researchers are investigating scanning ultrasound as a drug delivery vehicle in order to increase the effectiveness of drugs designed for dementia and, potentially, other neurological disorders.   


How will we recruit for the trial? 

The University of Queensland, through the Queensland Brain Institute, has partnered with a Clinical Research Organisation which will undertake the safety trial. The Clinical Research Organisation will recruit participants for the trial, according to rigorous criteria for which ethical approval will be in place. The initial safety trial will involve a small group of participants, probably fewer than 50 people. 

People who are interested in participating in the trials will be able to find out more information regarding eligibility once the trial has received approval to begin, from the Australian New Zealand Clinical Trials Registry:  


Is QBI keeping a list of people interested in participating in the clinical trial? 

No, QBI is unable to keep a list of interested parties as recruitment will be through an independent Clinical Research Organisation. Refer to Australian New Zealand Clinical Trials Registry: to keep up-to-date with progress on the trial once it has been approved to begin. 


If you have already received the funds required to commence the clinical trials, then why are you asking for more donations?

These clinical trials are testing just one of a number of possible methods for treating dementia – learning more about the disease and its causes remains a primary point of focus for our scientists and clinicians. Researchers across the University are approaching this issue with different strategies and donor funding will help these projects significantly. The more support received, the more likely we will reach positive outcomes, treatments and understandings sooner. 


How much of my donation actually goes to the cause? 

When you give through The University of Queensland, 100 per cent of donor contributions go to your nominated cause. 


How can I find out more? 

Information on the project’s progress will be made available periodically through QBI's website. You can also subscribe to the CJCADR newsletter below: